PT3796912T - Compostos antiproliferativos e anticorpo biespecífiico contra bcma e cd3 para uso combinado - Google Patents

Compostos antiproliferativos e anticorpo biespecífiico contra bcma e cd3 para uso combinado

Info

Publication number
PT3796912T
PT3796912T PT197324940T PT19732494T PT3796912T PT 3796912 T PT3796912 T PT 3796912T PT 197324940 T PT197324940 T PT 197324940T PT 19732494 T PT19732494 T PT 19732494T PT 3796912 T PT3796912 T PT 3796912T
Authority
PT
Portugal
Prior art keywords
bispecific antibody
antibody against
combined use
antiproliferative compounds
against bcma
Prior art date
Application number
PT197324940T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of PT3796912T publication Critical patent/PT3796912T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT197324940T 2018-05-23 2019-05-22 Compostos antiproliferativos e anticorpo biespecífiico contra bcma e cd3 para uso combinado PT3796912T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862675639P 2018-05-23 2018-05-23

Publications (1)

Publication Number Publication Date
PT3796912T true PT3796912T (pt) 2023-05-17

Family

ID=66999900

Family Applications (1)

Application Number Title Priority Date Filing Date
PT197324940T PT3796912T (pt) 2018-05-23 2019-05-22 Compostos antiproliferativos e anticorpo biespecífiico contra bcma e cd3 para uso combinado

Country Status (25)

Country Link
US (3) US11439637B2 (https=)
EP (2) EP4218762A3 (https=)
JP (2) JP7293256B2 (https=)
KR (1) KR102813281B1 (https=)
CN (2) CN112399848B (https=)
AU (1) AU2019274530B2 (https=)
BR (1) BR112020023704A2 (https=)
CA (1) CA3101050A1 (https=)
CY (1) CY1126060T1 (https=)
DK (1) DK3796912T5 (https=)
EA (1) EA202092830A1 (https=)
ES (1) ES2945214T3 (https=)
FI (1) FI3796912T3 (https=)
HR (1) HRP20230449T1 (https=)
HU (1) HUE061792T2 (https=)
IL (1) IL278853B2 (https=)
LT (1) LT3796912T (https=)
MX (1) MX420366B (https=)
PL (1) PL3796912T3 (https=)
PT (1) PT3796912T (https=)
RS (1) RS64189B1 (https=)
SG (1) SG11202011545YA (https=)
SI (1) SI3796912T1 (https=)
SM (1) SMT202300142T1 (https=)
WO (1) WO2019226761A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI791552B (zh) * 2017-07-10 2023-02-11 美商西建公司 抗增生化合物及其使用方法
BR112020023756A2 (pt) 2018-05-23 2021-02-09 Celgene Corporation tratamento de mieloma múltiplo e uso de biomarcadores para 4-(4-(4-(((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)benzil)piperazin-1-il)-3-fluorobenzonitrila
WO2020097403A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
JP2020103414A (ja) * 2018-12-26 2020-07-09 株式会社三洋物産 遊技機
RS67646B1 (sr) * 2019-01-09 2026-02-27 Celgene Corp Čvrsti oblici koji obuhvataju (s)-4-(4-(4-(((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-4-il)oksi)metil) benzil)piperazin-1-il)-3-fluorobenzonitril i soli istog, kao i kompozicije koje obuhvataju i metode korišćenja istih
WO2020146440A1 (en) * 2019-01-09 2020-07-16 Celgene Corporation Antiproliferative compounds and second active agents for use in treating multiple myeloma
AU2020206692B2 (en) 2019-01-09 2025-03-27 Celgene Corporation Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
EP3819007B1 (en) 2019-11-11 2024-07-10 Amgen Research (Munich) GmbH Dosing regimen for anti-bcma agents
US20230114674A1 (en) * 2020-01-20 2023-04-13 Kangpu Biopharmaceuticals, Ltd. Isoindoline derivative, and pharmaceutical composition and use thereof
JP2021133198A (ja) * 2020-02-28 2021-09-13 株式会社三洋物産 遊技機
JP2021133200A (ja) * 2020-02-28 2021-09-13 株式会社三洋物産 遊技機
JP2021133199A (ja) * 2020-02-28 2021-09-13 株式会社三洋物産 遊技機
CN116157125A (zh) * 2020-04-28 2023-05-23 朱诺治疗学股份有限公司 针对bcma的t细胞疗法与免疫调节化合物的组合
JP2023524068A (ja) 2020-04-30 2023-06-08 ブリストル－マイヤーズ スクイブ カンパニー サイトカイン関連有害事象を治療する方法
JP2021186294A (ja) * 2020-05-29 2021-12-13 株式会社三洋物産 遊技機
JP2022012088A (ja) * 2020-06-30 2022-01-17 株式会社三洋物産 遊技機
JP2022012090A (ja) * 2020-06-30 2022-01-17 株式会社三洋物産 遊技機
JP2022012089A (ja) * 2020-06-30 2022-01-17 株式会社三洋物産 遊技機
US12472176B2 (en) 2020-07-07 2025-11-18 Celgene Corporation Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
FI4284512T3 (fi) 2021-01-28 2025-05-22 Regeneron Pharma Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi
CN119546329A (zh) 2022-04-11 2025-02-28 瑞泽恩制药公司 用于通用肿瘤细胞杀伤的组合物和方法
KR20250151441A (ko) 2023-02-17 2025-10-21 리제너론 파마슈티칼스 인코포레이티드 Cd3/taa 이중특이적 항체에 대해 반응성인 유도된 nk 세포
WO2026059921A1 (en) * 2024-09-10 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bcma inhibitors in combination with lag3 inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5948893A (en) 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
JP2013532153A (ja) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
PL3988117T3 (pl) * 2015-04-13 2025-03-10 Pfizer Inc. Przeciwciała terapeutyczne i ich zastosowania
US10683369B2 (en) * 2015-08-03 2020-06-16 Engmab Sàrl Monoclonal antibodies against BCMA
US10238225B2 (en) * 2016-06-08 2019-03-26 Windor Enterprises, LLC Compression garment donning aid device, method, and kit
WO2018075820A2 (en) 2016-10-20 2018-04-26 Celgene Corporation Cereblon-based heterodimerizable chimeric antigen receptors
EP4295918A3 (en) 2016-11-02 2024-03-20 Bristol-Myers Squibb Company Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
TWI791552B (zh) * 2017-07-10 2023-02-11 美商西建公司 抗增生化合物及其使用方法

Also Published As

Publication number Publication date
AU2019274530B2 (en) 2024-09-19
RS64189B1 (sr) 2023-06-30
EP3796912A1 (en) 2021-03-31
US20240366593A1 (en) 2024-11-07
JP7293256B2 (ja) 2023-06-19
FI3796912T3 (fi) 2023-05-11
SG11202011545YA (en) 2020-12-30
EA202092830A1 (ru) 2021-04-08
JP2021525248A (ja) 2021-09-24
EP4218762A3 (en) 2023-08-16
HUE061792T2 (hu) 2023-08-28
DK3796912T5 (da) 2024-08-19
JP7550922B2 (ja) 2024-09-13
KR20210021996A (ko) 2021-03-02
JP2023116613A (ja) 2023-08-22
US12053466B2 (en) 2024-08-06
PL3796912T3 (pl) 2023-09-11
CA3101050A1 (en) 2019-11-28
EP3796912B1 (en) 2023-02-15
IL278853B2 (en) 2025-06-01
EP4218762A2 (en) 2023-08-02
US11439637B2 (en) 2022-09-13
IL278853B1 (en) 2025-02-01
CN112399848B (zh) 2024-09-06
AU2019274530A1 (en) 2020-12-10
US20230181575A1 (en) 2023-06-15
WO2019226761A1 (en) 2019-11-28
CN112399848A (zh) 2021-02-23
US20190381035A1 (en) 2019-12-19
SI3796912T1 (sl) 2023-07-31
MX420366B (es) 2025-02-10
BR112020023704A2 (pt) 2021-02-17
CN113713095A (zh) 2021-11-30
HRP20230449T1 (hr) 2023-07-21
KR102813281B1 (ko) 2025-05-28
CY1126060T1 (el) 2023-11-15
CN113713095B (zh) 2025-07-15
ES2945214T3 (es) 2023-06-29
DK3796912T3 (da) 2023-05-15
IL278853A (en) 2021-01-31
MX2020012485A (es) 2021-04-28
SMT202300142T1 (it) 2023-07-20
LT3796912T (lt) 2023-06-12

Similar Documents

Publication Publication Date Title
PT3796912T (pt) Compostos antiproliferativos e anticorpo biespecífiico contra bcma e cd3 para uso combinado
CY2025020I2 (el) ΑΜΦΙΕΙΔΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-BCMA X αντι-CD3 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
PT3802608T (pt) Anticorpos anti-cd3 e utilizações destes
CY2023007I1 (el) Anti-bcma αντισωματα, διειδικα μορια συνδεσης αντιγονου που συνδεουν bcma και cd3, και χρησεις αυτων
EP3889179A4 (en) Bispecific antibody and use thereof
IL280029A (en) Ror-1 specific chimeric antigen receptors and uses thereof
DK3411402T3 (da) Bcma- og cd3-bispecifikke t-celle-engagerende antistofkonstruktioner
IL283945A (en) Anti-cd28 and anti-cd22 bispecific antibodies and their uses
IL290255A (en) Anti-ctla4/anti-pd-1 bispecific antibody and use thereof
IL253166B (en) Bispecific antibodies against cd3 and cd20
IL264334A (en) Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
BR112017011914A2 (pt) ?antígeno de maturação de célula b de direcionamento de anticorpos e métodos de uso?
SG11202006583VA (en) Pharmaceutical compositions comprising bispecific antibodies directed against cd3 and cd20 and their uses
PL3328889T3 (pl) Konstrukty przeciwciała dwuswoistego wiążące DLL3 i CD3
KR102587633B9 (ko) 수의학적 용도를 위한 인터류킨-31 단클론성 항체
HUE054384T2 (hu) EGFRVIII-T és CD3-at kötõ bispecifikus antitest-konstrukciók
MX2017003022A (es) Anticuerpos anti-cll-1 e inmunoconjugados.
IL285909A (en) Anti-bcma chimeric antigen receptors
UY37083A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso
EP4013512C0 (en) BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD3
EP3802622A4 (en) NEW BISPECIFIC ANTI-CD3 / ANTI-CD20 ANTIBODY
IL281717A (en) Antibody formulation
EP3897720A4 (en) BAFF-R BISPECIFIC T-LYMPHOCYTE ACTIVATING ANTIBODIES
IL280281A (en) Anti-cd40 antibodies and uses thereof
IL271346A (en) Bispecific antibodies and methods of making and using thereof